- Home
- SILO
SILO
Silo Pharma Inc.
as 11-15-2024 4:00pm EST
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | SARASOTA |
| Market Cap: | 5.9M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 150.8K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.15 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.84 - $4.50 | Next Earning Date: | 11-12-2024 |
| Revenue: | $72,102 | Revenue Growth: | N/A |
| Revenue Growth (this year): | 1.86% | Revenue Growth (next year): | N/A |
Latest Silo Pharma Inc. News
SILO Breaking Stock News: Dive into SILO Ticker-Specific Updates for Smart Investing
Simply Wall St.
3 days ago
Silo Pharma Third Quarter 2024 Earnings: US$0.22 loss per share (vs US$0.21 loss in 3Q 2023)
GlobeNewswire
18 days ago
Silo Pharma Reports Positive Results in Sterilization and Dissolution Testing of SP-26 Ketamine Implant
GlobeNewswire
2 months ago
Silo Pharma Announces Completion of FDA Pre-IND Meeting to Advance Development of SPC-15 for Treatment of PTSD
GlobeNewswire
3 months ago
Silo Pharma Expands Development Agreement with Sever Pharma for Novel Ketamine Implant Therapeutic
GlobeNewswire
3 months ago
Silo Pharma Announces Partnership with Global CRO for Central Nervous System Homing Peptide
GlobeNewswire
4 months ago
Silo Pharma to Present at H.C. Wainwright Annual Global Investment Conference
GlobeNewswire
4 months ago
Silo Pharma Announces Closing of $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
GlobeNewswire
4 months ago
Silo Pharma Announces $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Compare SILO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SILO Silo Pharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.